3 active not recruiting, 3 recruiting, 3 terminated, 2 completed. 8 Phase 1, 7 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Active not recruiting 2, Recruiting 2, Terminated 2, Completed 1, Withdrawn 1 |
| Phase 2 | 7 | Active not recruiting 3, Terminated 2, Completed 1, Recruiting 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow Refractory Mycosis Fungoides: new trials by email Literature Review of Refractory Mycosis Fungoides trials Research Report on Refractory Mycosis Fungoides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab Non-Interventional Study - Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome | Recruiting | City of Hope Medical Center | 100 | 2024-12-06 | 2026-09-14 | |
| Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment Biospecimen Collection, Computed Tomography, Magrolimab - Mycosis Fungoides, Recurrent Mycosis Fungoides | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 8 | 2021-04-06 | 2025-10-16 |
| Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine - Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 45 | 2020-07-18 | 2026-09-30 |
| Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas Brentuximab Vedotin, Lenalidomide, Laboratory Biomarker Analysis - CD30-Positive Neoplastic Cells Present, Folliculotropic Mycosis Fungoides | Phase 1 | Withdrawn | City of Hope Medical Center | 2019-03-01 | 2019-04-30 | |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-04 | 2026-05-26 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Belinostat, Carfilzomib, Copanlisib Hydrochloride - Breast Adenocarcinoma, Metastatic Breast Carcinoma | Phase 1 | Terminated | Mayo Clinic | 17 | 2018-03-27 | 2025-05-26 |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2017-11-14 | 2026-09-30 |
| Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides Aminolevulinic Acid Hydrochloride, Photodynamic Therapy, Quality-of-Life Assessment - Refractory Mycosis Fungoides | Early Phase 1 | Completed | Mayo Clinic | 11 | 2017-11-13 | 2023-01-05 |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 68 | 2017-09-27 | 2026-08-13 |
| Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Laboratory Biomarker Analysis, Nivolumab - Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma | Phase 2 | Terminated | Mayo Clinic | 12 | 2017-05-17 | 2020-04-21 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm | Phase 1 | Recruiting | Mayo Clinic | 99 | 2017-04-04 | 2026-06-10 |
| Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma Durvalumab, Laboratory Biomarker Analysis, Lenalidomide - Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 78 | 2017-03-08 | 2026-07-31 |
| Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides Quality-of-Life Assessment, Objective Grading of Skin Findings - Recurrent Mycosis Fungoides, Refractory Mycosis Fungoides | Suspended | Vanderbilt-Ingram Cancer Center | 60 | 2016-05-22 | 2026-08-19 |
Mycosis Fungoides (13) · Lymphoma, T-Cell (7) · Lymphoma, Large-Cell, Anaplastic (6) · Lymphoma, T-Cell, Cutaneous (6) · Sezary Syndrome (5) · Immunoblastic Lymphadenopathy (4) · Enteropathy-Associated T-Cell Lymphoma (2) · Lymphoma, B-Cell (2) · Adenocarcinoma, Papillary (1) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Breast Neoplasms (1) · Carcinoma, Basal Cell (1) · Carcinoma, Basosquamous (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Signet Ring Cell (1)
Hemic and Lymphatic Diseases (13) · Immune System Diseases (13) · Immunoproliferative Disorders (13) · Lymphatic Diseases (13) · Lymphoma (13) · Lymphoproliferative Disorders (13) · Neoplasms (13) · Neoplasms by Histologic Type (13) · Lymphoma, Non-Hodgkin (12) · Lymphoma, T-Cell, Cutaneous (7) · Lymphoma, T-Cell (6) · Lymphadenopathy (4) · Neoplasms by Site (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3)
Nivolumab (4) · Biopsy (3) · Disulfides (3) · Immunoglobulin G (3) · Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · pembrolizumab (3) · Cyclophosphamide (2) · Depsipeptides (2) · Lactones (2) · Lenalidomide (2) · romidepsin (2) · 1-phenyl-3,3-dimethyltriazene (1) · 10-propargyl-10-deazaaminopterin (1) · AFM13 (1)
City of Hope Medical Center (4) · Mayo Clinic (4) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · Vanderbilt-Ingram Cancer Center (1)
United States (13)
Aaron Mangold (1) · Alex F Herrera (1) · Austin Kirschner, MD, PhD (1) · Christiane Querfeld (1) · Christiane Querfeld, MD (1) · Grzegorz S. Nowakowski, M.D. (1) · Jasmine Zain, MD (1) · Joselle Cook, M.B.B.S. (1) · Michael S Khodadoust (1) · Nora Bennani, M.D. (1) · Stephen Ansell (1) · Swaminathan P Iyer, MD (1) · Yago L Nieto (1)
PMID 32632956, PMID 33333150, PMID 35175355, PMID 35750419, PMID 36898933, PMID 39951620, PMID 40186077
P30CA015083 (1), P30CA033572 (1), P30CA068485 (1), P50CA186781 (1), R01CA229510 (1), R01CA262613 (1), UM1CA186709 (1), UM1CA186716 (1), UM1CA186717 (1)